Cereno Scientific
Cereno Scientific is a Swedish clinical-stage biotech company developing epigenetic therapies for rare cardiovascular and pulmonary diseases. Its pipeline centers on HDAC-modulating programs, including CS1, CS014 and CS585, which are being advanced through preclinical and clinical development.
Fiscal year 2025 · change from previous year
Development 2023–2025
Business
Share of revenueDevelopment of CS1 for pulmonary arterial hypertension and related cardiopulmonary indications.
Development of CS014 through early clinical testing and Phase II preparation.
Preclinical development of CS585, a selective prostacyclin receptor agonist.
Translational research, regulatory work, and external partnering support across the pipeline.
Customers
Cereno Scientific does not sell commercial medicines today; its direct counterparties are regulators, clinical trial participants, research partners, and potential licensing partners. The eventual end customers for its therapies are patients with rare cardiovascular and pulmonary diseases, especially pulmonary arterial hypertension and related conditions.
Ultimately buy the therapeutic benefit through prescribed medicines for PAH and related indications.
May partner on later-stage assets that show differentiated clinical and regulatory progress.
CROs, investigators, and academic collaborators support trial execution and data generation.
FDA and other agencies review trial design, safety, and development pathways.
Strategy
Cereno Scientific’s strategy is to advance its HDAC-based pipeline through clinical milestones that reduce development uncertainty and increase partnering value. The company also uses regulatory designations, external collaborations, and a lean operating model to progress multiple programs while preserving flexibility.
Clinical data and trial progress are the main value drivers for a biotech without commercial revenue.
Fast Track and similar designations can improve development efficiency and partnering appeal.
Later-stage clinical assets may attract larger pharma partners or licensing discussions.
Platform breadth can create multiple shots on goal across cardiopulmonary diseases.
Geography
Cereno Scientific is headquartered in Sweden and operates as a Nordic biotech with a global clinical and partnering footprint. Its development work is international, with collaborations in the United States and participation in conferences and partnering events across Europe, North America and Asia.
Risks
The company’s value depends on successful clinical development, regulatory acceptance, and access to financing before any product revenue exists. As a clinical-stage biotech, it also faces binary trial risk, dilution risk, and the possibility that scientific results do not translate into approved therapies or partnering deals.
- Clinical development failureImpact: CriticalLikelihood: Medium
Pipeline value depends on positive safety, efficacy, and tolerability data in small patient populations.
Exposure - Financing and dilution riskImpact: HighLikelihood: High
The company is pre-revenue and must fund multi-year trials and regulatory work.
Exposure: Corporate funding runway
- Regulatory riskImpact: HighLikelihood: Low
Trial design, endpoints, and agency feedback can alter timelines and development costs.
Exposure: FDA interactions and Phase II planning
- Partnering and commercialization riskImpact: MediumLikelihood: Medium
Future value may depend on securing collaborations or licensing on favorable terms.
Exposure: Business development
Accounting
Judgemental itemsClinical and preclinical costs are expensed as incurred, so trial timing drives reported losses.
Impact: Quarterly and annual results can swing with study activity and external service spend
Equity-linked financing can create finance costs, fair value effects, and dilution.
Impact: Reported earnings and share count may be affected by conversion terms
The company must demonstrate access to future capital to fund ongoing development.
Impact: Disclosure and valuation depend on financing assumptions
Similar listed companies
Publicly listed companies with a comparable business focus.
Mereo BioPharma Group plc
MREO · Pharmaceutical Preparations
Mereo BioPharma Group plc is a biopharmaceutical company focused on developing late-stage therapies for rare diseases.
Crispr Therapeutics AG
CRSP · Biological Products, (No Diagnostic Substances)
CRISPR Therapeutics AG is a gene-editing biopharmaceutical company built around CRISPR/Cas9 technology and the development of gene-based medicines for serious diseases.
Cero Therapeutics Holdings, Inc.
CERO · Biological Products, (No Diagnostic Substances)
Editas Medicine, Inc.
EDIT · Biological Products, (No Diagnostic Substances)
Editas Medicine is a U.S.-based biotechnology company focused on developing gene-editing medicines using CRISPR-based platforms.
Crescent Biopharma, Inc
CBIO · Pharmaceutical Preparations
Spero Therapeutics, Inc.
SPRO · Pharmaceutical Preparations
Last updated: 24/09/2026